[
  {
    "ts": null,
    "headline": "Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab",
    "summary": "Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab Five patients receiving ravulizumab did not achieve meaningful LDH control compared to one patient receiving poze-cemdi; after switching to the combination, four of the five previously treated with ravulizumab achieved LDH control A separat",
    "url": "https://finnhub.io/api/news?id=595aae37a359577be95c03c7bca9040e820f62e19886a6f238e59c0dcb3143a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733616000,
      "headline": "Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab",
      "id": 131854628,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab Five patients receiving ravulizumab did not achieve meaningful LDH control compared to one patient receiving poze-cemdi; after switching to the combination, four of the five previously treated with ravulizumab achieved LDH control A separat",
      "url": "https://finnhub.io/api/news?id=595aae37a359577be95c03c7bca9040e820f62e19886a6f238e59c0dcb3143a8"
    }
  },
  {
    "ts": null,
    "headline": "Kymera: Protein Degradation Could Drive Dupixent-Like Value",
    "summary": "Kymera Therapeutics is a biotech company with promising candidates in its pipeline for inflammatory disorders. Read why KYMR stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=302582cb326a21b4f9ea4643e0f5df82c5c3a2828b4d1f19193bdd97bd7cd835",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733533679,
      "headline": "Kymera: Protein Degradation Could Drive Dupixent-Like Value",
      "id": 131835702,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2178839740/image_2178839740.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Kymera Therapeutics is a biotech company with promising candidates in its pipeline for inflammatory disorders. Read why KYMR stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=302582cb326a21b4f9ea4643e0f5df82c5c3a2828b4d1f19193bdd97bd7cd835"
    }
  }
]